Literature DB >> 27134258

Analysis of Systemic Sclerosis-associated Genes in a Turkish Population.

F David Carmona1, Ahmet Mesut Onat2, Tamara Fernández-Aranguren2, Alberto Serrano-Fernández2, Gema Robledo2, Haner Direskeneli2, Amr H Sawalha2, Sule Yavuz2, Javier Martín2.   

Abstract

OBJECTIVE: To evaluate the genetic background of systemic sclerosis (SSc) in the Turkish population.
METHODS: There were 354 cases and 718 unaffected controls from Turkey genotyped for the most relevant SSc genetic markers (IRF5-rs10488631, STAT4-rs3821236, CD247-rs2056626, DNASE1L3-rs35677470, IL12A-rs77583790, and ATG5-rs9373839). Association tests were conducted to identify possible associations.
RESULTS: Except for ATG5, all the analyzed genes showed either significant associations (IRF5: p = 1.32E-05, OR 1.76; CD247: p = 2.20E-03, OR 0.75) or trends of association (STAT4: p = 0.066, OR 1.21; IL12A: p = 0.079, OR 4.07; DNASE1L3: p = 0.097, OR 1.41) with the overall disease or with specific phenotypes.
CONCLUSION: The genetic component of SSc seems to be similar between Turks and Europeans.

Entities:  

Keywords:  GENETICS; SYSTEMIC SCLEROSIS; TURKEY

Mesh:

Substances:

Year:  2016        PMID: 27134258     DOI: 10.3899/jrheum.160045

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  2 in total

Review 1.  The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms.

Authors:  Wenjie Zhao; Xiaoyang Yue; Kuai Liu; Junfeng Zheng; Runda Huang; Jun Zou; Gabriela Riemekasten; Frank Petersen; Xinhua Yu
Journal:  Rheumatol Int       Date:  2017-04-22       Impact factor: 2.631

2.  Association between STAT4 gene polymorphism and type 2 diabetes risk in Chinese Han population.

Authors:  Jiaqi Cui; Rui Tong; Jing Xu; Yanni Tian; Juan Pan; Ning Wang; Huan Chen; Yanqi Peng; Sijia Fei; Wang Ling; Chaoying Guo; Juanchuan Yao; Wei Cui
Journal:  BMC Med Genomics       Date:  2021-06-27       Impact factor: 3.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.